Regeneron Pharmaceuticals

At $10.4M in disclosed federal lobbying, Regeneron Pharmaceuticals ranks as a major spender — well above the typical filer. Outlays in this range generally reflect a sustained presence in Washington, with at least one full-time government affairs lead and a stable of outside lobbyists engaged on the organization's priority issues.

Across the 5-year window from 2020 to 2024, Regeneron Pharmaceuticals's annual disclosed lobbying spend has climbed sharply — from $1.7M in 2020 to $2.6M in 2024, a change of +58%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Regeneron Pharmaceuticals's disclosed lobbying focuses on a narrow 4-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.

2 of 7 lobbyists reported by Regeneron Pharmaceuticals (29%) disclose prior federal government service. That share is common at established government affairs operations that explicitly hire from agency and committee staff.

Among the named bench, lobbyists with disclosed prior federal service include Michael D. Ferrell (Former Legislative Director, U.S. House of Representatives); Hunter H. Biden (Former Chief Counsel, House Ways & Means Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Regeneron Pharmaceuticals ranks #17 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Regeneron Pharmaceuticals's $10.4M sits 37% below the sector average.

Regeneron Pharmaceuticals's LobbySpend Influence Score of 53/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.

Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.